SCHEMBL5723347

SCHEMBL5723347

CSc1ccc(-c2cc3c(cc2C(O)c2cccc(C)c2)OCO3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.36
MAPT P10636 4/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CFTR P13569 1/20 0.34
ALDH1A1 P00352 5/20 0.33
HPGD P15428 4/20 0.33
EDNRA P25101 2/20 0.33
EPHX1 P07099 1/20 0.33
MAOB P27338 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 4/20 0.32
LMNA P02545 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
PTGS1 P23219 3/20 0.32
PTGS2 P35354 3/20 0.32
USP2 O75604 2/20 0.32
ALOX12 P18054 2/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723125 0.88 EDNRA (0.39) GAAMAPTTP53MEN1KMT2A
SCHEMBL5723821 0.88 PTGS2 (0.41) GAAMAPTTP53MEN1KMT2A
SCHEMBL6139589 0.86 CYP1A2 (0.39) MAPTKMT2AEDNRAALOX15RAB9A
SCHEMBL6139744 0.82 GAA (0.41) GAAMAPTTP53MEN1KMT2A
SCHEMBL5723503 0.82 PTGS2 (0.52) MAOBPTGS1PTGS2
SCHEMBL5723730 0.81 PTGS2 (0.39) GAAMAPTTP53MEN1KMT2A
SCHEMBL5723681 0.81 PTGS2 (0.34) GAAMAPTTP53MEN1KMT2A
SCHEMBL5723608 0.78 PTGS2 (0.36) GAAMAPTTP53MEN1KMT2A
SCHEMBL6591351 0.73 PTGS1 (0.51) GAAMAPTTP53MEN1KMT2A
SCHEMBL6139079 0.72 EDNRA (0.36) MAPTTP53MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406609-B1 SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-09-06 EP disclosed
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2005-03-17 US disclosed
US-6825185-B2 IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR NITROMED, INC. 2004-11-30 US disclosed
US-20040116431-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2004-06-17 US disclosed
US-6706724-B2 ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT NITROMED, INC. 2004-03-16 US disclosed
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications NICOX S.A. (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGES, PTGER4, PTGS1 GAA 3487/4885MAPT 4270/4885TP53 4491/4885
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications PTGS2, PTGES2, PTGES GAA 2936/4885MAPT 3968/4885TP53 4672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.